|
MechanismP2Y12 receptor agonists |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.KR |
First Approval Date01 Aug 2010 |
100 Clinical Results associated with Southern Cross Pharma Pty Ltd.
0 Patents (Medical) associated with Southern Cross Pharma Pty Ltd.
100 Deals associated with Southern Cross Pharma Pty Ltd.
100 Translational Medicine associated with Southern Cross Pharma Pty Ltd.